

NICE PUBLIC HEALTH PROGRAMME GUIDANCE

Type 2 diabetes: preventing pre-diabetes among adults in high-risk groups

3rd meeting of the Programme Development Group Thursday 25th March 2010

NICE offices, Mid City Place, 71 High Holborn, London WC1V 6NA

Attendees:	<p><i>Programme Development Group (PDG) Members:</i> Nick Wareham, Bennett Quinn, Anne Dornhorst, Jennifer Tringham, Neel Basudev, Mieria Jofre-Bonet (PM only), Steven Cummins, Tim Marsh, Margaret Guy, Wasim Hanif, Aderonke Jomo-Coco, Nigel Unwin, Marc Suhrcke, Sarah Wild</p> <p><i>Co-opted member:</i> Amanda Adler</p> <p><i>NICE:</i> Catherine Swann, Clare Wohlgemuth, Alastair Fischer, Emma Doohan, Adrienne Cullum, Karen Peploe, Ruaraidh Hill, Mike Kelly (AM only)</p> <p><i>Review Team:</i> Maxine Johnson and Nick Payne (SchARR)</p>
Apologies:	<p><i>Programme Development Group (PDG) Members:</i> Ameet Bakhai, Marie Cummins, Sabina Syed, Saiyyidah Zaidi, Akeem Ali</p>

Agenda Item		Action
1. Welcome and introductions	<p>Apologies were received from Ameet Bakhai, Marie Cummins, Sabina Syed, Saiyyidah Zaidi and Akeem Ali.</p> <p>It was noted that Sarah Spiers has resigned from the PDG.</p> <p><i>Minutes of the last meeting</i> The minutes were accepted as an accurate record.</p> <p>Action: Emma to publish minutes on website.</p> <p><i>Update of actions/matters arising:</i></p> <ul style="list-style-type: none"> • List of possible experts to present expert testimony to be passed to Nick Wareham • SchARR to make revisions to reviews following the last meeting. • The recommendations developed at the last meeting 	<p style="text-align: center;">Emma Doohan</p> <p style="text-align: center;">NICE team</p> <p style="text-align: center;">SchARR</p> <p style="text-align: center;">NICE team</p>

	<p>were circulated for comment by the PDG. Recommendations from this meeting, with the amended list from the last meeting, will be circulated before meeting 4.</p> <p>Declarations of Interest</p> <p>No new DOIs.</p>	
<p>2. Alastair Fischer: Health economics</p>	<p>Alastair Fischer presented a paper suggesting a possible way of approaching the health economics for this topic given the lack of evidence on the prevention of pre-diabetes.</p> <p>The PDG were given an opportunity to raise any questions or make comments on the presentation.</p> <p>Action point:</p> <ul style="list-style-type: none"> • It was agreed that the issues raised will be revisited at a later stage. 	
<p>3. Mike Kelly: Illness labelling</p>	<p>Mike Kelly presented an expert paper on chronic illness, labelling and stigma.</p> <p>The PDG were given an opportunity to ask any questions or raise any discussion points.</p> <p>Action points:</p> <ul style="list-style-type: none"> • An academic paper on this topic should be developed following the publication of the guidance. • The PDG will need to consider how to incorporate some of this literature into the development of the guidance 	
<p>4. Nigel Unwin: socio-economic position and risk factors</p>	<p>Nigel Unwin presented an expert paper on 'socio-economic position, the risk of pre and type 2 diabetes, and the implications for prevention'.</p> <p>The PDG had a discussion on the points raised during the morning's presentations.</p> <p>Action points:</p> <ul style="list-style-type: none"> • Nigel Unwin's paper to be circulated to the PDG. • The PDG to give further consideration to whether a population or targeted approach to the prevention of pre-diabetes in high-risk groups to be taken. 	<p>NICE</p>
<p>5. SchARR evidence review</p>	<p>Maxine Johnson from SchARR presented the findings from the second evidence review on pre-diabetes risk factors and Black and Minority Ethnic (BME) groups.</p> <p>The PDG were given an opportunity to ask any questions or make any comments on the review.</p>	

	<p>Action point:</p> <ul style="list-style-type: none"> Thought should be given as to whether it is possible to incorporate relevant research from outside of the UK. Non-UK data is outside the current search terms for the reviews. The PDG to forward any useful papers that should be considered for inclusion to SchHARR via NICE. <p>Nick Payne from SchHARR presented an outline of the structure of the SchHARR conceptual/ economic model.</p> <p>The PDG commented on the proposed model.</p> <p>Actions point:</p> <ul style="list-style-type: none"> The PDG agreed that they shouldn't just concentrate on obesity and diabetes, but should also consider other relevant risk factors. 	<p>NICE team/ SchHARR</p>
<p>6. Draft recommendations and considerations</p>	<p>Clare Wohlgemuth outlined the process for developing recommendations.</p> <p>The PDG divided into 3 groups to draft recommendations and considerations based on review 2 and the expert testimony heard during the morning.</p> <p>Each group considered the following:</p> <p>Whose health will benefit? Who should take action? What action should they have?</p>	
<p>7. Feedback from Groups</p>	<p>Each group presented their draft recommendations and considerations for discussion.</p> <p>The NICE team collected notes from each group.</p> <p>Action point: The NICE team will transcribe the recommendations and considerations into a word document, and circulate to the PDG for comment</p>	<p>NICE team</p>
<p>8. Glossary</p>	<p>Ruaraidh Hill proposed a process for developing a glossary for the guidance.</p> <p>Action point:</p> <ul style="list-style-type: none"> An example of terms used in previous guidance glossaries should be circulated to the PDG. 	<p>NICE team</p>
<p>9. Summary & AOB</p>	<p>The input from the expert papers were considered extremely helpful and will help to inform both the recommendations and the considerations.</p> <p>The PDG agreed that the scope of the evidence needs to extend beyond the UK. The PDG agreed that it would be</p>	

	<p>important to consider evidence from developed countries with similar demographics to the UK. The PDG considered the format that they would like this new evidence to be presented. It was agreed that the review should consider the promotion of a healthy diet, physical activity and weight change in minority ethnic groups in North America, Australia, New Zealand and Europe.</p> <p>Action points:</p> <ul style="list-style-type: none"> • NICE team to talk to SchARR to see whether they can take this new review forward. • Expert testimony – PDG to report back on any suitable suggestions • The Chair will meet with the NICE team to consider the preferred direction of travel for the guidance. The PDG to comment on any process issues. 	<p>NICE team</p> <p>PDG</p>
<p>Close and date of next meeting</p>	<p>Date of next meeting: 26th May 2010, Royal College of Anaesthetists, 35 Red Lion Square</p>	